NexGel Inc (NXGL)
NASDAQ:NXGL
Want to see NXGL full AI Analyst Report?
NXGL Stock Chart & Stats
$1.64
-$0.06(-1.71%)
At close: 4:00 PM EST
$1.64
-$0.06(-1.71%)
Day’s Range― - ―
52-Week Range$0.48 - $2.89
Previous CloseN/A
Volume27.00K
Average Volume (3M)50.95K
Market Cap
$6.81M
Enterprise Value$9.46M
Total Cash (Recent Filing)$208.00K
Total Debt (Recent Filing)$4.19M
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Aug 18, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding9,131,055
10 Day Avg. Volume60,354
30 Day Avg. Volume50,949
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)2.84
Price to Sales (P/S)1.11
P/FCF Ratio-9.17
Enterprise Value/Market Cap1.39
Enterprise Value/Revenue0.84
Enterprise Value/Gross Profit2.16
Enterprise Value/Ebitda-3.26
Forecast
1Y Price Target
$2.00Price Target Upside21.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.37
Revenue Forecast (FY)$24.06M
Bulls Say, Bears Say
Bulls Say
Transformative AcquisitionAcquiring BioNX materially expands NexGel’s addressable market with six commercial regenerative biomaterial products and existing reimbursement. This shortens commercialization lead times, boosts recurring revenue potential and supports scale efficiencies that can sustainably improve margins and profitability.
Strategic Partnership & Board StrengthSequence’s investment and board appointments bring manufacturing, distribution and capital markets expertise. That alignment should materially aid integration, provide contract manufacturing capacity, and improve go-to-market execution — durable operational support for scaling the regenerative portfolio.
Improving Product EconomicsGross margin improvement to ~39% (TTM) indicates stronger product economics from hydrogel IP and manufacturing progress. As revenue scales via acquisitions and contract manufacturing, sustaining higher gross margins enables operating leverage and a credible path to durable profitability if SG&A is controlled.
Bears Say
Near-Term Liquidity PressureLimited cash (~$1.8M) and negative operating cash flow (-$1.4M TTM) leave little runway versus an estimated incremental ~$500k/month operating run‑rate post-acquisition. Reliance on recent convertible financings and insider notes makes the company sensitive to execution delays and additional capital needs.
Rising LeverageLeverage rising to roughly parity with equity weakens financial flexibility for a small company. Elevated debt and convertible obligations increase refinancing and dilution risk if operating cash generation lags, constraining ability to invest in commercialization without further external capital.
Execution & Timing RiskPro forma projections depend on rapid BioNX integration and recognition of revenue; Q1 excluded that business and legacy consumer lines underperformed. The company faces integration, commercial ramp and SG&A step‑up risks that could delay profit accretion and pressure near‑term operating results.
NexGel Inc News
NXGL FAQ
What was NexGel Inc’s price range in the past 12 months?
NexGel Inc lowest stock price was $0.48 and its highest was $2.89 in the past 12 months.
What is NexGel Inc’s market cap?
NexGel Inc’s market cap is $6.81M.
When is NexGel Inc’s upcoming earnings report date?
NexGel Inc’s upcoming earnings report date is Aug 18, 2026 which is in 75 days.
How were NexGel Inc’s earnings last quarter?
Currently, no data Available
Is NexGel Inc overvalued?
According to Wall Street analysts NexGel Inc’s price is currently Undervalued.
Does NexGel Inc pay dividends?
NexGel Inc does not currently pay dividends.
What is NexGel Inc’s EPS estimate?
NexGel Inc’s EPS estimate is -0.12.
How many shares outstanding does NexGel Inc have?
NexGel Inc has 9,131,055 shares outstanding.
What happened to NexGel Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of NexGel Inc?
Currently, no hedge funds are holding shares in NXGL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NexGel Inc
NexGel Inc (NXGL) is a specialized healthcare company that focuses on the development and commercialization of innovative hydrogels and other products primarily for the medical and personal care markets. The company operates in the healthcare sector, providing solutions that cater to wound care, drug delivery, and personal care applications. NexGel's core products include hydrogel-based formulations that offer unique properties such as moisture retention and biocompatibility, making them suitable for a variety of therapeutic uses.
NXGL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized a transformational acquisition (BioNX), strategic financing and partnership with Sequence LifeScience, strengthened leadership, a commercial product portfolio in ~500 hospitals, and pro forma projections to triple revenue to ~$35M and be accretive — all significant positives. Offsetting these are near‑term operational and liquidity pressures: Q1 revenue declined ~5.7% YoY, cash on hand fell to $1.8M, SG&A is elevated, and some legacy consumer products and key customer relationships have underperformed. Management reported early signs of recovery and initial BioNX sales beginning in Q2, but timing and execution risk remain notable.View all NXGL earnings summariesNXGL Stock 12 Month Forecast
Average Price Target
$2.00
▲(21.95% Upside)
Technical Analysis
Retractable Technologies
―
Milestone Scientific
―
Precision Optics Corporation
―
Sanara MedTech
―
Femasys
―
Ownership Overview
13.06% Insiders
1.14% Mutual Funds
0.96% Other Institutional Investors
84.30% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---